Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial.
Vibeke StrandLaure GossecLaura C CoatesAlexis OgdieJiyoon ChoiBrandon BeckerJoe ZhuoThomas LehmanMiroslawa NowakAyanbola ElegbePhillip J MeaseAtul A DeodharPublished in: Arthritis care & research (2024)
Deucravacitinib demonstrated significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA and warrants further study. This article is protected by copyright. All rights reserved.